Uri Yablonka - 01 Jan 2025 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role
EVP & Chief Business Officer, Director
Signature
/s/ Uri Yablonka
Issuer symbol
BCLI
Transactions as of
01 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Jan 2025, 17:34:08 UTC
Previous filing
13 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCLI Common Stock Award $0 +40,000 +473% $0.000000 48,464 01 Jan 2025 Direct F1, F2
transaction BCLI Common Stock Award $0 +20,000 +41% $0.000000 68,464 01 Jan 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan (the "Plan"). The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
F2 Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024.
F3 Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.